N/A
N=194
Sensor and Electronic Health Records (EHR) Integration Pilot Study
Pulmonary Disease, Chronic Obstructive
Bottom Line
View on ClinicalTrials.gov: NCT03357341 ↗Enrolled (actual)
194
Serious AEs
0.0%
Results posted
Nov 2020
Primary outcome: Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) — -0.03; 0.07; -0.09; -0.08 Liter
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Mobile spirometer (Device); Device sensor (Device); Salbutamol (Drug); Activity monitor (Device); electronic diary card (Other); CAT (Other); ACT (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- GlaxoSmithKline
- Primary completion
- Sep 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Forced Expiratory Volume in One Second (FEV1) |
-0.03; 0.07; -0.09; -0.08; -0.06; -0.10 | — |
| PRIMARY Median Number of Steps Per Day |
3574; 2186; 4547; 2446; 3270; 2312 | — |
| PRIMARY Median Daily Activity Level Based on Vector Magnitude Counts. |
512; 378; 475; 415; 483; 389 | — |
| PRIMARY Patient Reported Outcome (PRO) Active Total Score |
75; 60.3; 75; 59; 73; 62.5 | — |
| PRIMARY PROactive Amount Domain Score |
61; 52; 61; 54; 57; 57 | — |
| PRIMARY PROactive Difficulty Domain Score |
84.5; 66; 86; 63; 82; 65 | — |
| PRIMARY Evaluating Respiratory Symptoms (E-RS) in COPD Total Score-COPD Cohort Only |
16.5; 17.8; 17.1; 15.5; 15.8; 16.3 | — |
| PRIMARY Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Event Rate-COPD Cohort Only |
2.06 | — |
| PRIMARY Number of Primary Care Visits for Asthma Conditions or COPD |
23; 79; 1; 21; 4; 17 | — |
| PRIMARY Number of Secondary Care Visits for Asthma Conditions or COPD |
0; 0; 0; 0 | — |
| PRIMARY Number of All Primary Care Visits |
426; 598; 7; 55; 87; 116 | — |
| PRIMARY Number of All Secondary Care Visits |
0; 0; 0; 0 | — |
| PRIMARY Number of Participants With New Prescriptions |
85; 85; 59; 48; 33; 52 | — |
| PRIMARY Number of Days in Hospital for Asthma and COPD |
0; 0 | — |
| PRIMARY Number of Participants Who Received Short-acting Beta-agonist Therapy |
85; 85 | — |
| PRIMARY Change From Baseline in COPD Assessment Test (CAT) Score-COPD Cohort Only |
0; 0; 1; 0.5; 1.5; 0 | — |
| PRIMARY Change From Baseline in Asthma Control Test (ACT) Score-asthma Cohort Only |
0; 0; 0; 0; 0; 0 | — |
| PRIMARY Median Rescue Medication Use |
0.3; 0.6; 0.2; 0.4; 0.1; 0.3 | — |
| PRIMARY Percentage of Participants With Maintenance Compliance |
68; 64; 59; 56; 54; 54 | — |
| PRIMARY Number of Participants Who Completed Exit Interview |
96; 80 | — |
Summary
This is a pilot study that will evaluate the feasibility of collecting increasing amounts of clinical study data from subjects through sensor and web/app based methods and integrating it with data from their EHR to facilitate more efficient and meaningful research with acceptable quality. Approximately 100 subjects with asthma and 100 subjects with chronic obstructive pulmonary disease (COPD) will be enrolled in this prospective study. The subjects will be identified through integrated EHR records following which eligible subjects will receive study devices and training on proper use of the devices at Baseline visit. Data will be collected remotely from subject reports, devices and sensors over six months.
Eligibility Criteria
Inclusion Criteria
COPD cohort
- Provide signed and dated informed consent form.
- Be willing to comply with all study procedures and be available for the duration of the study.
- Age >=40 years
- Diagnosed with COPD, defined as COPD listed on the subject's problem list and one of the following: a) At least one inpatient hospitalization with a COPD diagnosis listed as the primary or secondary diagnosis (J41.x, J42.x, J44.x [chronic bronchitis], J43.9 [emphysema] or J44.9 [Chronic obstructive pulmonary disease, unspecified]) in the last 12 months b) At least two outpatient encounters with a diagnosis of COPD exacerbation (J44.1), Acute bronchitis (J20.x), or bronchitis (J40) listed as the primary or secondary diagnosis, with different dates of service in the last 12 months c) At least one emergency room encounter with a COPD diagnosis (J41.x, J42.x, J44.x, J43.9, J44.9) listed as the primary or secondary diagnosis in the last 12 months d) At least two urgent care encounters with different dates of service, with a COPD diagnosis (J41.x, J42.x, J44.x, J43.9, J44.9) listed as the primary or secondary diagnosis in the last 12 months.
- At least one order for an inhaled COPD medication during the prior year.
- More than 12 months of data available in the integrated EHR data prior to date of screening.
Asthma cohort
- Provide signed and dated informed consent form.
- Be willing to comply with all study procedures and be available for the duration of the study.
- Age >=18 years
- Diagnosed with asthma, defined as asthma listed on the subject's problem list and one of the following: a) At least one inpatient hospitalization with an asthma diagnosis (J45.x) listed as the primary or secondary diagnosis in the last 12 months. b) At least one emergency room encounter with an asthma diagnosis (J45.x) listed as the primary or secondary diagnosis in the last 12 months c) at least two urgent care encounters, with different dates of service, with an asthma diagnosis (J45.x) listed as the primary or secondary diagnosis in the last 12 months d) At least three or more prescriptions or prescription refills in the past 12 months for any combination of the following: an inhaled glucocorticoid with or without a second controller (Montelukast, Theophylline, a long-acting beta agonist [LABA] alone) or a combination drug with a LABA and an inhaled glucocorticoid.
- More than 12 months of data available in the integrated EHR data prior to date of screening.
Exclusion Criteria
COPD cohort
- Inability/Unwillingness to use the required devices, or
- Inability to read and understand English Asthma cohort
- Inability/Unwillingness to use the required devices
- Inability to read and understand English
- Diagnosis of COPD listed on problem list
Data sourced from ClinicalTrials.gov (NCT03357341). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.